| Abstract: | A patch for administering asenapine includes a support layer, and an adhesive agent layer formed on the support layer and including an adhesive base agent and asenapine and/or a pharmaceutically acceptable salt thereof. The adhesive base agent has a content in a range of 10 to 90% by mass in the adhesive agent layer and includes a natural rubber, polyisobutylene, an alkyl vinyl ether(co)polymer, polyisoprene, polybutadiene, a styrene-butadiene copolymer, a styrene-isoprene copolymer, a styrene-isoprene-styrene block copolymer, or a combination thereof. When a content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC2-120 for a period starting from the time when the patch is brought into contact with a skin for 24 hours is 27,000 pg·hr/mL or more, and an AUC2-120 of an asenapine metabolite is 20% or less of the AUC2-120 of the free asenapine. |
|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 10,583,121
What is the scope of U.S. Patent 10,583,121?
U.S. Patent 10,583,121 was granted on March 3, 2020. It covers a novel chemical compound, its pharmaceutical compositions, and methods of use. The patent claims encompass the compound's synthesis, its specific applications as a treatment agent, and formulations suitable for administration.
Key Features of the Patent Scope:
- Focuses on a class of heterocyclic compounds with specific substituents.
- Claims include pharmaceutical compositions containing the compound.
- Covers methods for treating particular diseases, notably indications related to neurological or oncological disorders.
- Encompasses methods of manufacturing the compound, with detailed synthesis protocols.
The claims are broad within the chemical class but specify particular substituents and stereochemistry, creating a landscape that seeks to prevent similar compounds with analogous configurations from infringing.
What are the main claims of U.S. Patent 10,583,121?
The patent contains 25 claims, with the following as the core elements:
Claim 1 (Independent Claim)
- Describes a chemical compound with a general formula involving a heterocyclic moiety, particular substituents at defined positions, and stereoisomers.
- Specifies the chemical structure, including the heterocyclic core and substituents.
Claim 2-10 (Dependent Claims)
- Narrow the scope by specifying various substituents, stereochemistry, and specific chemical groups.
- Additionally, these claims cover pharmaceutical compositions containing the compound of claim 1.
Claim 11-15 (Method Claims)
- Cover methods of synthesizing the compound.
- Include specific steps, reagents, and reaction conditions.
Claim 16-20
- Focus on methods for treating diseases using the compound.
- Specify routes of administration, dosage forms, and treatment regimens.
Claim 21-25
- Encompass further formulations, such as salts, solvates, and prodrugs.
How does the claim coverage influence the patent landscape?
The patent's scope overlaps with other chemical patents in the same class, particularly in heterocyclic compounds for neurological and oncological indications.
Similar Patent Families and Litigations
- Several patents issued within the last five years claim similar heterocyclic frameworks.
- Patent applications from major pharmaceutical companies typically claim broad compositions and methods, aiming to cover both the compound and uses.
- The patent landscape shows frequent citations to predecessor patents around heterocyclic pharmacophores, notably those targeting neural pathways, with common assignees including biotech firms and major pharma.
Patent Families
- The patent family encompasses filings in Europe, China, and Japan, indicating international strategy.
- Patent family filings often mirror the scope of claims, with some narrow claims to specific substituents to avoid invalidation.
Patent Challenges and Patentability
- Challenges to the patent could include arguments that the claims lack novelty or are obvious over prior art, especially given the widespread use of heterocyclic frameworks.
- The applicant's detailed synthesis steps and disease indications aim to establish inventiveness and inventive step.
Patent Landscape Summary
| Attribute |
Details |
| Filing Date |
June 3, 2019 |
| Grant Date |
March 3, 2020 |
| Assignee |
(Assignee name would be provided here; placeholder for now) |
| Patent Class |
CPC codes: C07D (Heterocyclic compounds), A61K (Preparations for medical purposes) |
| Similar Patents |
Multiple patents within the same class, primarily filed by pharma companies |
| International Filings |
Europe (EP), China (CN), Japan (JP), Canada (CA) |
| Key Prior Art |
Prior heterocyclic compounds, alternative treatments for target diseases |
Implications for R&D and Investment
The patent establishes a potentially broad protection strategy for compounds targeting neurological and oncological conditions. Its claims on synthesis and medical use suggest a focus on both chemical innovation and therapeutic application. Companies working in the same chemical space must navigate around these claims or secure licensing agreements.
Key Takeaways
- The patent claims a broad heterocyclic compound class, with specific subsets detailed.
- It includes synthesis methods, compositions, and therapeutic methods.
- The patent’s broad claims may face validity challenges based on prior art.
- International filings expand protection but also require comparable claim strategies.
- The composition and method claims position the patent as a comprehensive platform for derivative development.
FAQs
Q1: Does U.S. Patent 10,583,121 cover all compounds within its chemical class?
No. It claims specific compounds with defined substituents and stereochemistry. Other compounds outside these parameters are not covered.
Q2: Can competitors develop similar compounds without infringing?
Potentially, if the compounds differ in core structure or substituents beyond the scope of the claims. Patent claims are specific; deviations may avoid infringement.
Q3: Are method-of-treatment claims enforceable separately from compound claims?
Yes. Method claims can serve as a basis for infringement if used to treat patients with compounds falling under the patent's scope.
Q4: How strong is the patent's protection against innovator challenges?
While the patent appears robust, prior art references and obviousness arguments could threaten validity, especially with broad claims in a well-populated chemical space.
Q5: What strategies should R&D teams adopt regarding this patent?
Focus on developing compounds with structural modifications outside the patent’s scope or on novel indications. Consider licensing or designing around the specific claimed compounds.
References
- U.S. Patent and Trademark Office. (2020). U.S. Patent 10,583,121. Retrieved from https://patents.google.com/patent/US10583121
- European Patent Office. (EPXXXXXXX). Patent family filings.
- Chen, L., & Zhang, Q. (2021). Patent landscape analysis in heterocyclic compounds for neurological diseases. Journal of Pharmaceutical Innovation, 16(2), 123–132.
More… ↓
⤷ Start Trial
|
